Status:
COMPLETED
A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Men
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The primary objective for this study is to assess the safety and tolerability of AZD8329 when given as a single dose in increasing dose strength, and also to identify the highest tolerated dose for fu...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures
- Have a body mass index between 19 and 30 kg/m2 and weigh at least 50 kg
Exclusion
- Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the result of the study, or the subject´s ability to participate
- Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00935662
Start Date
July 1 2009
End Date
August 1 2010
Last Update
September 13 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Linköping, Sweden
2
Research Site
Uppsala, Sweden